Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China
This article was originally published in The Pink Sheet Daily
The MOU with Pfizer enables the two companies to explore cooperation throughout the whole value chain, including R&D, product registration, commercialization, distribution and even manufacturing, SPH said.
You may also be interested in...
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector
Pfizer China Country Manager Wu Xiaobing And General Manager For Commercial And Diversified Business Kevin Xiao On Expansion To Rural Markets In China: An Interview With PharmAsia News
China recently announced it will increase its total healthcare funding for ongoing healthcare reform from RMB 850 billion ($124 billion) to RMB 1.134 trillion ($173 billion) to build up its basic medical infrastructure and expand reimbursement to more than 800 million rural residents. Pfizer Inc., the world's largest pharmaceutical company, began its geographic expansion in China seven years ago. Last year the company launched its "Spring Bud" program to expand training for rural doctors to expedite the company's entry into China's rural markets. The project initially covered the five provinces of Zhejiang, Yunnan, Fujian, Jilin and Shandong, and will now be expanded to include Guangdong, Guangxi, Sichuan, Liaoning, Henan and Hunan. In addition, Pfizer will sponsor training programs in more than 1,000 country hospitals in rural areas this year.